JP2016525113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525113A5 JP2016525113A5 JP2016527007A JP2016527007A JP2016525113A5 JP 2016525113 A5 JP2016525113 A5 JP 2016525113A5 JP 2016527007 A JP2016527007 A JP 2016527007A JP 2016527007 A JP2016527007 A JP 2016527007A JP 2016525113 A5 JP2016525113 A5 JP 2016525113A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- yloxy
- pyrazol
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 31
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002617 leukotrienes Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- -1 pyrrolidinonyl Chemical group 0.000 claims 2
- GMMIFPKQJYIPCZ-KRWDZBQOSA-N (2s)-2-hydroxy-1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 GMMIFPKQJYIPCZ-KRWDZBQOSA-N 0.000 claims 1
- SGFUUDAUBFRRPH-GOSISDBHSA-N (3r)-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]pyrrolidin-3-ol Chemical compound C1[C@H](O)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 SGFUUDAUBFRRPH-GOSISDBHSA-N 0.000 claims 1
- SGFUUDAUBFRRPH-SFHVURJKSA-N (3s)-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]pyrrolidin-3-ol Chemical compound C1[C@@H](O)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 SGFUUDAUBFRRPH-SFHVURJKSA-N 0.000 claims 1
- VRNHRFCAVNZHII-VWLOTQADSA-N (3s)-3-hydroxy-1-[1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperidin-4-yl]pyrrolidin-2-one Chemical compound O=C1[C@@H](O)CCN1C1CCN(CC=2C=C3C=CC(OC=4N=CC(=CC=4)C=4NN=CC=4)=CC3=NC=2)CC1 VRNHRFCAVNZHII-VWLOTQADSA-N 0.000 claims 1
- BQMOHLGGHREEOB-UHFFFAOYSA-N 1-[3-[[methyl-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]amino]methyl]azetidin-1-yl]ethanone Chemical compound C=1N=C2C=C(OC=3N=CC(=CC=3)C=3NN=CC=3)C=CC2=CC=1CN(C)CC1CN(C(C)=O)C1 BQMOHLGGHREEOB-UHFFFAOYSA-N 0.000 claims 1
- HQDICABEXSAXJK-UHFFFAOYSA-N 1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 HQDICABEXSAXJK-UHFFFAOYSA-N 0.000 claims 1
- OKCQFTWHXBDEDJ-UHFFFAOYSA-N 1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 OKCQFTWHXBDEDJ-UHFFFAOYSA-N 0.000 claims 1
- BPZOKXWKXHSEOJ-UHFFFAOYSA-N 1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperidin-4-ol Chemical compound C1CC(O)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 BPZOKXWKXHSEOJ-UHFFFAOYSA-N 0.000 claims 1
- WVYXHIHDEUSURN-UHFFFAOYSA-N 2,2-dimethyl-1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 WVYXHIHDEUSURN-UHFFFAOYSA-N 0.000 claims 1
- ZTWXFZSEBOQTMV-HXUWFJFHSA-N 2-hydroxy-1-[(3r)-3-[methyl-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]amino]pyrrolidin-1-yl]ethanone Chemical compound CN([C@H]1CN(CC1)C(=O)CO)CC(C=C1C=C2)=CN=C1C=C2OC(N=C1)=CC=C1C1=CC=NN1 ZTWXFZSEBOQTMV-HXUWFJFHSA-N 0.000 claims 1
- ZTWXFZSEBOQTMV-FQEVSTJZSA-N 2-hydroxy-1-[(3s)-3-[methyl-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]amino]pyrrolidin-1-yl]ethanone Chemical compound CN([C@@H]1CN(CC1)C(=O)CO)CC(C=C1C=C2)=CN=C1C=C2OC(N=C1)=CC=C1C1=CC=NN1 ZTWXFZSEBOQTMV-FQEVSTJZSA-N 0.000 claims 1
- KAYMQWUWXUHUGU-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)(O)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 KAYMQWUWXUHUGU-UHFFFAOYSA-N 0.000 claims 1
- GCZZTAIYOQHIMB-HXUWFJFHSA-N 2-hydroxy-n-methyl-n-[(3r)-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]pyrrolidin-3-yl]acetamide Chemical compound C1[C@H](N(C)C(=O)CO)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 GCZZTAIYOQHIMB-HXUWFJFHSA-N 0.000 claims 1
- GCZZTAIYOQHIMB-FQEVSTJZSA-N 2-hydroxy-n-methyl-n-[(3s)-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]pyrrolidin-3-yl]acetamide Chemical compound C1[C@@H](N(C)C(=O)CO)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 GCZZTAIYOQHIMB-FQEVSTJZSA-N 0.000 claims 1
- MMDQTGNLXQXGGN-UHFFFAOYSA-N 2-hydroxy-n-methyl-n-[1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperidin-4-yl]acetamide Chemical compound C1CC(N(C)C(=O)CO)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 MMDQTGNLXQXGGN-UHFFFAOYSA-N 0.000 claims 1
- TVJFWQGNCRMXTQ-UHFFFAOYSA-N 2-methoxy-1-[4-[[7-[5-(1H-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]ethanone 1-[[7-[5-(1H-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]azetidin-3-ol Chemical compound OC1CN(Cc2cnc3cc(Oc4ccc(cn4)-c4ccn[nH]4)ccc3c2)C1.COCC(=O)N1CCN(Cc2cnc3cc(Oc4ccc(cn4)-c4ccn[nH]4)ccc3c2)CC1 TVJFWQGNCRMXTQ-UHFFFAOYSA-N 0.000 claims 1
- TYQFYVYCKZCRQG-UHFFFAOYSA-N 2-methyl-1-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 TYQFYVYCKZCRQG-UHFFFAOYSA-N 0.000 claims 1
- LMLZGWZOVMFXRY-UHFFFAOYSA-N 3-[1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperidin-4-yl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1CCN(CC=2C=C3C=CC(OC=4N=CC(=CC=4)C=4NN=CC=4)=CC3=NC=2)CC1 LMLZGWZOVMFXRY-UHFFFAOYSA-N 0.000 claims 1
- JSIXHLXAGSLVFU-UHFFFAOYSA-N 3-methyl-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]azetidin-3-ol Chemical compound C1C(C)(O)CN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 JSIXHLXAGSLVFU-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- UJCLDEJIIDCLMM-UHFFFAOYSA-N OCC(=O)N1CCN(Cc2cnc3cc(Oc4ccc(cn4)-c4ccn[nH]4)ccc3c2)CC1 Chemical compound OCC(=O)N1CCN(Cc2cnc3cc(Oc4ccc(cn4)-c4ccn[nH]4)ccc3c2)CC1 UJCLDEJIIDCLMM-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- DIRGZKJGPPSACG-UHFFFAOYSA-N cyclopropyl-[4-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperazin-1-yl]methanone Chemical compound C1CN(CC=2C=C3C=CC(OC=4N=CC(=CC=4)C=4NN=CC=4)=CC3=NC=2)CCN1C(=O)C1CC1 DIRGZKJGPPSACG-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- OXLCEIIBHVACRX-UHFFFAOYSA-N n,n-dimethyl-1-[[7-[5-(1h-pyrazol-5-yl)pyridin-2-yl]oxyquinolin-3-yl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)C)CCN1CC1=CN=C(C=C(OC=2N=CC(=CC=2)C=2NN=CC=2)C=C2)C2=C1 OXLCEIIBHVACRX-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846137P | 2013-07-15 | 2013-07-15 | |
| US61/846,137 | 2013-07-15 | ||
| PCT/US2014/046489 WO2015009609A1 (en) | 2013-07-15 | 2014-07-14 | Inhibitors of leukotriene production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525113A JP2016525113A (ja) | 2016-08-22 |
| JP2016525113A5 true JP2016525113A5 (enExample) | 2017-08-31 |
| JP6353899B2 JP6353899B2 (ja) | 2018-07-04 |
Family
ID=51261274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527007A Active JP6353899B2 (ja) | 2013-07-15 | 2014-07-14 | ロイコトリエン生成の阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9303018B2 (enExample) |
| EP (1) | EP3022193B1 (enExample) |
| JP (1) | JP6353899B2 (enExample) |
| WO (1) | WO2015009609A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2016000127A1 (en) | 2013-12-20 | 2017-10-06 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors. |
| UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918092A (en) | 1983-12-21 | 1990-04-17 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
| US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
| DE4127849A1 (de) | 1991-08-22 | 1993-02-25 | Merck Patent Gmbh | Benzodioxanderivate |
| US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| DE19705450A1 (de) | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| US5925654A (en) * | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| DE19821003A1 (de) | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AP2001002319A0 (en) | 2000-10-26 | 2001-12-31 | Pfizer Prod Inc | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. |
| US20060019269A1 (en) | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| PT1572215E (pt) | 2002-12-20 | 2009-12-09 | Glaxo Group Ltd | Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| WO2006105304A2 (en) | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Phenyl and pyridyl lta4h modulators |
| BRPI0616187A2 (pt) | 2005-09-21 | 2011-06-14 | Decode Genetics Ehf | composto, composiÇço farmacÊutica, e, uso de uma quantidade terapeuticamente eficaz de um composto |
| CA2636929A1 (en) | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
| WO2007073405A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| TW200823187A (en) | 2006-10-24 | 2008-06-01 | Wyeth Corp | Benzodioxane derivatives and uses thereof |
| WO2011032050A2 (en) * | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
| WO2011114220A1 (en) | 2010-03-18 | 2011-09-22 | Biotechnology Research Corporation Limited | Neuro-protective effects of adelostemma gracillimum and its isolated compounds |
| AP3339A (en) * | 2011-03-14 | 2015-07-31 | Boehringer Ingelheim Int | Benzodioxane inhibitors of leukotriene production |
| US9139567B2 (en) | 2011-07-19 | 2015-09-22 | Boehringer Ingelheim International Gmbh | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase |
| JP6080226B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン |
| AR091315A1 (es) | 2012-03-06 | 2015-01-28 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno |
| WO2014014874A1 (en) | 2012-07-17 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Pyrazole derivatives which inhibit leukotriene production |
-
2014
- 2014-07-14 WO PCT/US2014/046489 patent/WO2015009609A1/en not_active Ceased
- 2014-07-14 EP EP14745322.9A patent/EP3022193B1/en active Active
- 2014-07-14 JP JP2016527007A patent/JP6353899B2/ja active Active
- 2014-07-14 US US14/330,297 patent/US9303018B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| RU2011105151A (ru) | Азольные соединения | |
| JP2019501125A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2014501732A5 (enExample) | ||
| MA45130B1 (fr) | Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein | |
| JP2018515555A5 (enExample) | ||
| EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
| JP2014526500A5 (enExample) | ||
| JP2016517878A5 (enExample) | ||
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2017519781A5 (enExample) | ||
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| JP2016512511A5 (enExample) | ||
| MA38071B1 (fr) | Formes cristallines d'un inhibiteur de facteur xia | |
| JP2013532709A5 (enExample) | ||
| CO6150139A2 (es) | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su | |
| JP2017529365A5 (enExample) | ||
| JP2017503765A5 (enExample) | ||
| MA42016A1 (fr) | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires | |
| JP2017502063A5 (enExample) | ||
| EP4162937A4 (en) | Pharmaceutical composition for preventing or treating parkinson's disease, comprising 2-(4-(1-hydroxypropane-2-yl)phenyl)isoindoline-1-one compound |